• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

测量银屑病关节炎的疾病活动度。

Measuring disease activity in psoriatic arthritis.

作者信息

Wong Priscilla C H, Leung Ying-Ying, Li Edmund K, Tam Lai-Shan

机构信息

Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.

出版信息

Int J Rheumatol. 2012;2012:839425. doi: 10.1155/2012/839425. Epub 2012 Dec 25.

DOI:10.1155/2012/839425
PMID:23319952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3540792/
Abstract

Over the past decade, the assessment of the disease activity in psoriatic arthritis (PsA) has rapidly evolved in view of the need for valid, feasible, and reliable outcome measures that can be ideally employed in longitudinal cohorts, clinical trials, and clinical practice as well as the growing paradigm of tight disease control and treating to target in the management of PsA. This paper reviews the currently available measures used in the assessment of the disease activity in PsA. The composite measures for PsA that are under development are also discussed.

摘要

在过去十年中，鉴于需要有效、可行且可靠的疗效指标，以便理想地应用于纵向队列研究、临床试验及临床实践，同时考虑到银屑病关节炎（PsA）管理中疾病严格控制和靶向治疗这一不断发展的模式，PsA疾病活动度评估方法迅速发展。本文综述了目前用于评估PsA疾病活动度的可用方法。还讨论了正在研发的PsA综合评估方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2e1/3540792/e1ca19cef0df/IJR2012-839425.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2e1/3540792/e1ca19cef0df/IJR2012-839425.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2e1/3540792/e1ca19cef0df/IJR2012-839425.001.jpg

相似文献

1
Measuring disease activity in psoriatic arthritis.测量银屑病关节炎的疾病活动度。
Int J Rheumatol. 2012;2012:839425. doi: 10.1155/2012/839425. Epub 2012 Dec 25.
2
Psoriatic arthritis assessment tools in clinical trials.临床试验中的银屑病关节炎评估工具
Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii49-54. doi: 10.1136/ard.2004.034165.
3
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.银屑病和银屑病关节炎研究与评估小组/风湿病学结局指标共识推荐意见及银屑病关节炎中使用复合指标和治疗目标的研究计划。
Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.
4
Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies.银屑病关节炎的治疗：早期诊断、疾病严重程度监测和前沿治疗。
J Autoimmun. 2017 Jan;76:21-37. doi: 10.1016/j.jaut.2016.10.009. Epub 2016 Nov 9.
5
A review of disease activity measures for psoriatic arthritis: what is the best approach?银屑病关节炎疾病活动度测量方法综述：最佳方法是什么？
Expert Rev Clin Immunol. 2014 Sep;10(9):1241-54. doi: 10.1586/1744666X.2014.943663. Epub 2014 Aug 4.
6
The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.多项综合结局工具评估的 TICOPA 试验中早期银屑病关节炎炎症严密控制的反应动力学。
Ann Rheum Dis. 2017 Oct;76(10):1688-1692. doi: 10.1136/annrheumdis-2017-211137. Epub 2017 Jun 12.
7
Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy.评估银屑病和银屑病关节炎的疾病活动度：对管理和治疗的影响
Expert Rev Clin Immunol. 2016;12(5):573-82. doi: 10.1586/1744666X.2016.1146133. Epub 2016 Feb 19.
8
Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group.关节炎性银屑病疾病严重程度和应答者指数的制定——OMERACT10 关节炎性银屑病特别兴趣小组的报告。
J Rheumatol. 2011 Jul;38(7):1496-501. doi: 10.3899/jrheum.110278.
9
Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative.实现银屑病临床试验中对银屑病关节炎评估的国际共识：国际皮肤病学结局测量（IDEOM）倡议。
Arch Dermatol Res. 2018 Nov;310(9):701-710. doi: 10.1007/s00403-018-1855-3. Epub 2018 Aug 25.
10
Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next Steps.2019 年 GRAPPA 研讨会关于评估银屑病关节炎的连续综合指数的结果和会员推荐的下一步措施。
J Rheumatol Suppl. 2020 Jun;96:11-18. doi: 10.3899/jrheum.200121.

引用本文的文献

1
Pain management, prolonged opioid use, initiated anti-rheumatic treatment and psychiatric morbidity in new-onset psoriatic arthritis.新发银屑病关节炎的疼痛管理、长期使用阿片类药物、开始抗风湿治疗及精神疾病发病率
Rheumatol Adv Pract. 2025 Apr 10;9(2):rkaf039. doi: 10.1093/rap/rkaf039. eCollection 2025.
2
Physical component of SF-36 is associated with measures of disease activity in patients with psoriatic arthritis: a real-life study from a tertiary referral centre.SF-36身体维度与银屑病关节炎患者的疾病活动度指标相关：一项来自三级转诊中心的真实世界研究
Rheumatol Int. 2024 Dec;44(12):2897-2904. doi: 10.1007/s00296-024-05727-w. Epub 2024 Oct 10.
3

本文引用的文献

1
GRAPPA Responder Index Project (GRACE): a report from the GRAPPA 2011 annual meeting.GRAPPA 应答器指数项目（GRACE）：GRAPPA 2011 年会报告。
J Rheumatol. 2012 Nov;39(11):2196-7. doi: 10.3899/jrheum.120822.
2
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project).候选复合疾病活动和反应指标在银屑病关节炎中的发展（GRACE 项目）。
Ann Rheum Dis. 2013 Jun;72(6):986-91. doi: 10.1136/annrheumdis-2012-201341. Epub 2012 Jul 13.
3
Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.
Risankizumab Efficacy in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Remission: A Case Report on Rheumatologic and Dermatologic Disease Manifestations with Literature Review.
司库奇尤单抗治疗滑膜炎、痤疮、脓疱病、骨肥厚和骨炎（SAPHO）缓解的疗效：1例关于风湿性和皮肤病表现的病例报告及文献综述
Case Reports Immunol. 2024 Mar 19;2024:9076852. doi: 10.1155/2024/9076852. eCollection 2024.
4
The Impact of Spondyloarthritis on Health-Related Quality of Life and Healthcare Resource Utilization in Saudi Arabia: A Narrative Review and Directions for Future Research.沙特阿拉伯脊柱关节炎对健康相关生活质量和医疗资源利用的影响：一项叙述性综述及未来研究方向
Open Access Rheumatol. 2023 Sep 8;15:161-171. doi: 10.2147/OARRR.S414530. eCollection 2023.
5
An integrative analysis to reveal that CLEC2B and ferroptosis may bridge the gap between psoriatic arthritis and cancer development.一项综合分析表明，CLEC2B 和铁死亡可能在银屑病关节炎和癌症发展之间架起桥梁。
Sci Rep. 2022 Aug 27;12(1):14653. doi: 10.1038/s41598-022-19135-2.
6
Consensus statements for evaluation and nonpharmacological Management of Psoriatic Arthritis in UAE.阿联酋中银屑病关节炎的评估和非药物治疗的共识声明。
Int J Rheum Dis. 2022 Jul;25(7):725-732. doi: 10.1111/1756-185X.14357. Epub 2022 Jun 9.
7
Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.真实世界中阿普米司特治疗比利时银屑病关节炎患者的疗效和安全性：前瞻性观察性 APOLO 研究结果。
Adv Ther. 2022 Feb;39(2):1055-1067. doi: 10.1007/s12325-021-02016-x. Epub 2022 Jan 3.
8
Disease activity indices in psoriatic arthritis: current and evolving concepts.银屑病关节炎的疾病活动指数：现状与进展。
Clin Rheumatol. 2021 Nov;40(11):4427-4435. doi: 10.1007/s10067-021-05774-9. Epub 2021 May 18.
9
Using functional genomics to advance the understanding of psoriatic arthritis.利用功能基因组学加深对银屑病关节炎的认识。
Rheumatology (Oxford). 2020 Nov 1;59(11):3137-3146. doi: 10.1093/rheumatology/keaa283.
10
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK.在英国，用司库奇尤单抗序贯生物疗法与苏金单抗治疗伴有中度至重度银屑病的活动性银屑病关节炎的成本效益分析。
Pharmacoecon Open. 2020 Dec;4(4):635-648. doi: 10.1007/s41669-020-00202-1.
复合疾病活动评分在银屑病关节炎中的应用对 PRESTA 数据集。
Ann Rheum Dis. 2012 Mar;71(3):358-62. doi: 10.1136/annrheumdis-2011-200093. Epub 2011 Oct 11.
4
Psoriatic arthritis: update on pathophysiology, assessment and management.银屑病关节炎：病理生理学、评估和管理的最新进展。
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i77-84. doi: 10.1136/ard.2010.140582.
5
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study.关节炎性银屑病患者的整体评估：一项多中心 GRAPPA 和 OMERACT 研究。
J Rheumatol. 2011 May;38(5):898-903. doi: 10.3899/jrheum.100857. Epub 2011 Feb 15.
6
Development of a preliminary composite disease activity index in psoriatic arthritis.初步制定银屑病关节炎的综合疾病活动指数。
Ann Rheum Dis. 2011 Feb;70(2):272-7. doi: 10.1136/ard.2010.129379. Epub 2010 Nov 29.
7
Disease measurement--enthesitis, skin, nails, spine and dactylitis.疾病测量--肌腱端炎、皮肤、指甲、脊柱和指骨炎。
Best Pract Res Clin Rheumatol. 2010 Oct;24(5):659-70. doi: 10.1016/j.berh.2010.05.004.
8
Informing response criteria for psoriatic arthritis (PsA). II: Further considerations and a proposal--the PsA joint activity index.报告关节炎性银屑病（PsA）反应标准。二：进一步的思考和建议——PsA 关节活动指数。
J Rheumatol. 2010 Dec;37(12):2559-65. doi: 10.3899/jrheum.100479. Epub 2010 Oct 15.
9
Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program.观察性队列研究：多伦多大学银屑病关节炎项目的经验教训。
Rheumatology (Oxford). 2011 Jan;50(1):25-31. doi: 10.1093/rheumatology/keq262. Epub 2010 Aug 6.
10
Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies.报告银屑病关节炎反应标准：I：基于 3 项抗肿瘤坏死因子随机研究数据的判别模型。
J Rheumatol. 2010 Sep;37(9):1892-7. doi: 10.3899/jrheum.091172. Epub 2010 Jul 1.